SetPoint Medical, focused on therapies for chronic autoimmune diseases, raised $140 million in private funding—$25 million from its Series C and $115 million from its Series D rounds, co-led by Elevage Medical Technologies and Ally Bridge Group.
Josh Makower, M.D., and Kevin Reilly joined the board, representing Elevage and Ally Bridge Group, respectively. New investors, including Northwell Health, SPRIG Equity, and others, participated alongside returning backers such as NEA, Abbott, and Boston Scientific.
To prepare for commercialization, SetPoint appointed Erik Styacich as Vice President of Sales and Spencer Bailey as Vice President of Market Access & Reimbursement.
How the funding will be used: The funds will support the launch of the SetPoint System for moderate-to-severe rheumatoid arthritis and further development of treatments for other autoimmune conditions.
KEY QUOTE:
“We are pleased to share these strategic milestones underpinning our commitment to a successful and seamless market launch for the SetPoint System in select U.S. markets this year, with broader national expansion in 2026. We are thrilled to welcome an outstanding group of new investors to our exceptional syndicate.”
Murthy V. Simhambhatla, Ph.D., CEO of SetPoint Medical
